secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066946
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences Q1 2025 net loss $8.8M; cash $91M; pipeline data expected in 2025
--------------------------------------------------------------------------------

- Net loss $8.8M ($1.17/diluted share) vs $9.1M in Q1 2024; revenue from Gilead collaboration $9.4M (up from $5.8M).
- Cash, equivalents and marketable securities $91.0M as of March 31, 2025; projected to fund operations into mid-2026.
- R&D expenses $14.9M (up from $11.9M) driven by ABI-6250 and ABI-5366; G&A $4.5M (slight decrease from $4.6M).
- Interim Phase 1b data for HSV candidates ABI-5366 and ABI-1179 expected in fall 2025; Phase 1a data for HDV candidate ABI-6250 in Q3 2025.
- Phase 1b data for HBV candidate ABI-4334 (400 mg cohort) expected in H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025066946/0000950170-25-066946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017025066946/asmb-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer